Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | FLT3 |
| Variant | I836del |
| Impact List | deletion |
| Protein Effect | gain of function |
| Gene Variant Descriptions | FLT3 I836del results in the deletion of an amino acid in the protein kinase domain activation loop of the Flt3 protein at amino acid 836 (PMID: 12663439). I836del results in constitutive phosphorylation of Flt3 and activation of Stat5, Erk signaling, leading to transformation of cultured cells (PMID: 15256420). |
| Associated Drug Resistance | |
| Category Variants Paths |
FLT3 mutant FLT3 act mut FLT3 I836del FLT3 mutant FLT3 exon20 FLT3 I836del |
| Transcript | NM_004119.3 |
| gDNA | chr13:g.28018500_28018502delGAT |
| cDNA | c.2508_2510delCAT |
| Protein | p.I836delI |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_004119.2 | chr13:g.28018500_28018502delGAT | c.2508_2510delCAT | p.I836delI | RefSeq | GRCh38/hg38 |
| XM_011535015.3 | chr13:g.28015679_28015681delATC | c.2506_2508delATG | p.M836delM | RefSeq | GRCh38/hg38 |
| NM_004119.3 | chr13:g.28018500_28018502delGAT | c.2508_2510delCAT | p.I836delI | RefSeq | GRCh38/hg38 |
| XM_011535015 | chr13:g.28015679_28015681delATC | c.2506_2508delATG | p.M836delM | RefSeq | GRCh38/hg38 |
| XM_017020486.2 | chr13:g.28015186_28015188delCAT | c.2506_2508delATG | p.M836delM | RefSeq | GRCh38/hg38 |
| XM_017020486 | chr13:g.28015186_28015188delCAT | c.2506_2508delATG | p.M836delM | RefSeq | GRCh38/hg38 |
| XM_011535015.2 | chr13:g.28015679_28015681delATC | c.2506_2508delATG | p.M836delM | RefSeq | GRCh38/hg38 |
| NM_004119 | chr13:g.28018500_28018502delGAT | c.2508_2510delCAT | p.I836delI | RefSeq | GRCh38/hg38 |
| XM_017020486.1 | chr13:g.28015186_28015188delCAT | c.2506_2508delATG | p.M836delM | RefSeq | GRCh38/hg38 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|